Corvus Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
CRVS
- Share Price
-
$1.49
- (As of Monday Closing)
Corvus Pharmaceuticals General Information
Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 863 Mitten Road
- Suite 102
- Burlingame, CA 94010
- United States
+1 (650) 000-0000
Corvus Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.49 | $1.46 | $0.61 - $4.19 | $73.1M | 49M | 282K | -$0.64 |
Corvus Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 36,472 | (7,177) | 39,738 | 51,076 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (31,497) | (41,594) | (42,766) | (5,903) |
| Net Income | (30,192) | (41,307) | (43,241) | (5,995) |
| Total Assets | 51,942 | 68,240 | 109,455 | 85,529 |
| Total Debt | 1,690 | 2,601 | 3,647 | 2,310 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Corvus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corvus Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Corvus Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target
Drug Discovery
Burlingame, CA
29
As of 2022
00000
000000 - 000
00000
0000 0
rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000 000000000
Cambridge, MA
00
As of 0000
00000
00000000
00000
00000
ncididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostru
0000000000000
Hayward, CA
000
As of 0000
00000
000000000
00000
Add Comparison
Corvus Pharmaceuticals Competitors (51)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 00000 00000000000 | Formerly VC-backed | Hayward, CA | 000 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Philadelphia, PA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
Corvus Pharmaceuticals Patents
Corvus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020373124-A1 | Immunomodulatory anti-cd73 antibodies and uses thereof | Pending | 01-Nov-2019 | 00000000000 | |
| CA-3159196-A1 | Immunomodulatory anti-cd73 antibodies and uses thereof | Pending | 01-Nov-2019 | 00000000000 | |
| EP-4051713-A1 | Immunomodulatory anti-cd73 antibodies and uses thereof | Pending | 01-Nov-2019 | 00000000000 | |
| AU-2019377454-A1 | B-cell activating cd73 antibodies | Pending | 05-Nov-2018 | 00000000000 | |
| CA-3118706-A1 | B-cell activating cd73 antibodies | Pending | 05-Nov-2018 | C07K16/2896 |
Corvus Pharmaceuticals Executive Team (11)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Richard Miller MD | Chief Executive Officer & Chairman | ||
| Leiv Lea | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | ||
| William Jones Ph.D | Senior Vice President | ||
| Terry Gould | President & Chairman | ||
| Peter Thompson MD | Co-Founder & Board Member |
Corvus Pharmaceuticals Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Edith Mitchell | Corvus Pharmaceuticals | Board Member | 000 0000 |
| Ian Clark | Self | Board Member | 000 0000 |
| Linda Grais MD | Self | Board Member | 000 0000 |
| Peter Thompson MD | Self | Co-Founder & Board Member | 000 0000 |
| Richard Miller MD | Corvus Pharmaceuticals | Chief Executive Officer & Chairman | 000 0000 |
Corvus Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Corvus Pharmaceuticals Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Angel Pharmaceuticals | Drug Discovery | Jiaxing, China | 0000 |
Corvus Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
